Drugs that contain Azilsartan Kamedoxomil
1. Edarbi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5583141 | AZURITY | Heterocyclic compounds and their use as angiotensin antagonists |
Dec, 2013
(10 years ago) | |
| US7157584 | AZURITY | Benzimidazole derivative and use thereof |
May, 2025
(1 year, 26 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958961 | AZURITY | Pharmaceutical composition for angiotensin II-mediated diseases |
Jun, 2014
(9 years ago) | |
| US7572920 | AZURITY | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(8 months from now) | |
| US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2016 |
NCE-1 date: 25 February, 2015
Market Authorisation Date: 25 February, 2011
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
How can I launch a generic of EDARBI before it's drug patent expiration?
More Information on Dosage
EDARBI family patents
